Form 4: Immunovant CTO Sells Shares to Cover Tax Obligations

Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,805 shares of common stock at $18.15 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Summary

• Jay S. Stout, Chief Technology Officer of Immunovant, Inc. (IMVT), reported a transaction involving the sale of common stock.
• On July 23, 2025, Mr. Stout sold 2,805 shares of Immunovant common stock at a price of $18.15 per share.
• The sale was a 'sell to cover' transaction, mandated by the Issuer's election to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs).
• This transaction was not a discretionary sale by Mr. Stout.
• The shares sold were linked to 6,250 RSUs that vested on July 17, 2025, which were part of a larger grant of 100,000 RSUs on April 17, 2023.
• Following this transaction, Mr. Stout beneficially owns 204,919 shares of Immunovant common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' to satisfy tax obligations upon RSU vesting, rather than a voluntary sale indicating a change in management's confidence in the company.

Future Outlook

This filing, a Form 4, reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction related to executive compensation and does not provide specific insights into broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in company fundamentals or management's outlook.

Key Dates

Keywords

Immunovant, IMVT, SEC Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Executive Compensation